Why IQVIA Stock Jumped 13% in a Week and Whether the Gains Can Last

IQV shares jump after Q2 earnings beat, record bookings and higher 2026 guidance, but future gains hinge on execution and backlog conversion.

Zacks Investment Research • Aug 4, 2026

Is IQVIA Stock a Buy as Growth Improves but High Leverage Persists?

IQV's proprietary data platform and expanding clinical research business support growth, but high debt and liquidity risks keep the investment outlook balanced.

Zacks Investment Research • Aug 4, 2026

IQVIA and Medera to Advance Cardiac Gene Therapy and Human-Based Drug Discovery

RESEARCH TRIANGLE PARK, N.C. & BOSTON--(BUSINESS WIRE)--IQVIA (NYSE:IQV), a leading global provider of clinical research services, commercial insights and healthcare intelligence to the life sciences and healthcare industries, and Medera Inc. (“Medera”), a clinical-stage biopharmaceutical company pioneering next-generation therapeutics for cardiovascular disease, today announced a strategic collaboration to accelerate the development of cardiac gene therapies and human-based drug discovery plat.

Business Wire • Aug 4, 2026

An IQVIA CEO Sold $26.1 Million as Bookings Hit a Record $3.15 Billion

The CEO of IQVIA executed an exercise-and-sell of stock appreciation rights involving shares at a weighted average price of $245.51 on July 29, 2026. Bousbib maintains substantial equity exposure through roughly 836,000 directly held shares and about 543,000 shares held indirectly via the Orohena Trust.

The Motley Fool • Aug 2, 2026

An IQVIA Insider Just Sold Over $1 Million in Stock. Here's What Long-Term Investors Should Know

The transaction involved the sale of 5,000 shares at $249.16 per share, representing a total value of about $1.2 million. This disposition resulted in a 19% reduction of the insider total direct equity holdings in the company.

The Motley Fool • Aug 2, 2026

An IQVIA Insider Sold Just Before the Stock Slipped. Here's What Long-Term Investors Should Know

The transaction involved the disposal of 558 shares at an exact weighted-average price of $245.21 per share on July 29, 2026. The sale reduced the insider's direct equity holdings by 16%, leaving 2,989 shares held directly.

The Motley Fool • Aug 2, 2026

IQVIA: A Great Business At The Wrong Price (Rating Downgrade)

IQVIA Holdings Inc. operates behind the scenes, running clinical trials and processing vast healthcare data for pharmaceutical companies. IQV's business spans clinical trial management, healthcare data analytics, software products, and consulting, providing diversified revenue streams. I previously rated IQV a Buy due to strong results and robust demand, but concerns over slowing guidance, CSMS segment weakness, and regulatory risks tempered my enthusiasm.

Seeking Alpha • Jul 29, 2026

IQVIA raises annual profit forecast on clinical research demand

IQVIA Holdings raised its annual profit forecast on Tuesday after reporting better-than-expected second-quarter results, driven by strong ​demand for its healthcare data and analytics services, ‌sending its shares up 11% before the bell.

Reuters • Jul 28, 2026

Clinical Trials Provider Soars, Clears Buy Point On Solid Q2 Results

Citing improved organic revenue growth, the company raised full-year revenue guidance.

Investors Business Daily • Jul 28, 2026

IQVIA Q2 Earnings Call Highlights

IQVIA NYSE: IQV reported second-quarter results that exceeded the high end of its guidance, supported by accelerating organic revenue growth, higher R&D Solutions bookings and operational productivity gains. The company also raised its full-year outlook for revenue, adjusted EBITDA and adjusted diluted earnings per share.

MarketBeat • Jul 28, 2026